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STI & PrEP Updates
Marshal Miller, MD, AAHIVS
Sunny Lai, MD, MPH
April 29, 2020

Lecture Objectives
• Apply key findings from the DISCOVER trial to PrEP clinical decisionmaking
• Understand the gaps in PrEP research for cisgender women and
adolescents
• Understand the use of on-demand pre-exposure prophylaxis
• Review Current treatment recs and emerging data on Gonococcal
and Chlamydial infection
• Discuss diagnostic and management options for non-gonococcal
urethritis

Case 1: Switching to Descovy for PrEP?
• 20-year-old man presents for his three-month PrEP visit.
• He has been seeing a lot of lawsuit ads on TV that Truvada is
dangerous.
• He heard that Descovy is now an option.
• He asks for your opinion about switching to Descovy.
• How would you advise him?

PrEP Timeline
• 2012: FDA approved Truvada for HIV
pre-exposure prophylaxis for adults
at risk for acquiring HIV
• 2018: Truvada was approved for
adolescents weighing at least 35 kg
• 2019: USPSTF made a level A
recommendation to offer PrEP to
persons at high risk of HIV
acquisition
• 2019: FDA approved Gilead’s
Descovy for PrEP for MSM and TGW,
not for cis women who engage in
receptive vaginal sex
https://www.statnews.com/2020/02/26/newest-prep-pill-hiv-prevention-fuel-progress-or-profits/

CDC, 2018; FDA Briefing Document, 2019; USPSTF, JAMA, 2019.

Truvada vs. Descovy
Name

Tenofovir

Emtricitabine

Renal Function

Population

Truvada

Tenofovir
disoproxil
fumarate (TDF)
300 mg

Emtricitabine
(FTC), 200 mg

Not
recommended
if CrCl <60
mL/min

MSM
TGW
Heterosexual
PWID

Emtricitabine
(FTC), 200 mg

Not
recommended
if CrCl <30
mL/min

MSM
TGW

Descovy Tenofovir
alafenamide
(TAF)
25 mg

Prescribing PrEP
Gay, Bisexual, and other Men who
have Sex with Men, and
Transgender Women
Sexual partner with HIV
Recent bacterial STD
High number of sex partners
History of inconsistent or no
condom use
• Commercial sex work
•
•
•
•

Heterosexual Men and Women

Sexual partner with HIV
Recent bacterial STD
High number of sex partners
History of inconsistent or no
condom use
• Commercial sex work
• Lives in high prevalence area or
network
•
•
•
•

Descovy and Truvada: approved for adolescents (>35 kg)
Truvada is safe in use in pregnancy and breastfeeding

People who inject drugs

• HIV-positive injecting partner
• Sharing injection equipment
• High risk sexual behavior

PrEP Labs and Monitoring
Lab Screening and Visits
Initial visit

•
•
•
•
•

HIV test (ideally 4th
gen HIV ag/ab)
Cr
HbsAb/Ag
HAV Ab
HCV Ab

•
•
•

Pregnancy test
GC/CT (site-specific)
Syphilis

•

Offer HAV, HBV
and HPV immunization
as indicated

Week 1

Call, check if Rx filled, assess adherence and side effects

Month 1 (optional)

Assess adherence and side effects

Every 3 months

• HIV testing, assess s/sx of acute HIV
• Repeat pregnancy test for women who may become pregnant
• STI testing

At least every 6 months

CrCl

At least every 12 months

Evaluate need to continue PrEP

Time to steady state levels of TFV-DP:
Maximum intracellular concentrations of TFV-DP are reached in:
• Blood after 20 days of daily oral dosing
• Rectal tissue after 7 days of daily oral dosing
• Cervico-vaginal tissues at 20 days of daily oral dosing

CDC 2017

Side effects

Image credit: Please PrEP Me Navigator Manual

Metabolism of TDF vs. TAF
Image Credit: University of Washington, National HIV Curriculum

300 mg

25 mg

TDF

Safety
Profiles of
TDF vs. TAF

(Studies in PLWH)
1Gupta

et al. AIDS. 2019
2Grant, P and Cotter, A. Curr
Opin HIV AIDS. 2016; 3Wang et
al. Medicine. 2016; 4Sax et al.
Clin Infect Dis. 2019

• Renal Toxicity: ⇧ Prox. Tubule
Dysfunction, GFR, Cr1-3
• Bone Toxicity: ⇩ BMD2,3
• ⬄Weight4, ⬄/⇧ Lipids3

TAF
• More favorable renal and bone profile1-3
• ⇧ Weight4
• ⇧ TC, LDL, HDL; ⇔ TC:HDL3

What’s the safety data in people on PrEP?

Grade 1 Cr: 1.11.3x upper limit
of normal
Grade 2 Cr: 1.11.8x upper limit
of normal

Pilkington et al. J Virus Erad. 2018

DISCOVER: Study Design
• International, randomized, double-blind, active-controlled non-inferiority phase III
trial
Wk 96
HIV and HBV-negative cis-MSM
and transgender women at
high risk of HIV* with eGFR
≥ 60 mL/min; previous
PrEP use permitted
(N = 5387)

FTC/TAF 200/25 mg + FTC/TDF Placebo QD
(n = 2694)
FTC/TDF 200/300 mg + FTC/TAF Placebo QD
(n = 2693)

Option for
open-label FTC/TAF
up to Wk 144

*Condomless anal sex ≥ 2 times with ≥ 2 unique partners in past 12 wks or rectal gonorrhea, rectal chlamydia, or syphilis in past 24 wks.

• Prevention services (eg, risk reduction, condoms/lubricant) and adherence
counseling provided at entry and every 12 wks
• Endpoints of current analysis: HIV incidence and safety, including renal AEs and
biomarkers, bone fractures, BMD, and metabolic parameters at Wk 96
Ogbuagu. CROI 2020. Abstr 92.

Slide credit: clinicaloptions.com

DISCOVER: Baseline Characteristics
Characteristic

FTC/TAF
(n = 2694)

FTC/TDF
(n = 2693)

Median age, yrs (range)

34 (18-76)

34 (18-72)

Race, n (%)
§ White
§ Black
§ Asian

2264 (84)
240 (9)
113 (4)

2247 (84)
234 (9)
120 (5)

Hispanic/Latinx ethnicity, n (%)

635 (24)

683 (25)

45 (2)

29 (1)

HIV risk factors, n (%)
§ Condomless receptive anal sex with ≥ 2 partners in past 12 wks
§ Rectal gonorrhea in past 24 wks
§ Rectal chlamydia in past 24 wks
§ Syphilis in past 24 wks
§ Recreational drug use in past 12 wks
§ Binge drinking (≥ 6 drinks on ≥ 1 occasion; ≥ 1 time/mo)

1616 (62)
274 (10)
342 (13)
230 (9)
1785 (67)
618 (23)

1569 (60)
262 (10)
333 (12)
263 (10)
1786 (67)
599 (22)

Taking FTC/TDF for PrEP at baseline, n (%)

465 (17)

440 (16)

Transgender woman, n (%)

Ogbuagu. CROI 2020. Abstr 92.

Slide credit: clinicaloptions.com

FTC/TAF is non-inferior to FTC/TDF
• Noninferiority of FTC/TAF vs FTC/TDF for HIV prevention at Wk 96 established
• Upper bound of 95% CI of incidence rate ratio < 1.62
HIV Incidence

FTC/TAF (n = 2670)

FTC/TDF (n = 2655)

HIV infections, n

8

15

PY of follow-up

5029

5052

HIV incidence/100 PY

0.16

0.30

Current analysis at Wk 96†

Incidence rate ratio for FTC/TAF vs FTC/TDF (95% CI)

Ogbuagu. CROI 2020. Abstr 92.

0.54 (0.23-1.26)

Slide credit: clinicaloptions.com

DISCOVER: Safety Data Through Wk 96
• Both regimens well tolerated with low rates of discontinuation for AEs (1% to 2%)
• FTC/TAF associated with statistically significantly more favorable renal and bone
safety outcomes vs FTC/TDF
• More favorable eGFRCG changes in overall population, participants aged ≥ 50 yrs, and
participants with BL CrCl 60 to ≤ 90 mL/min (P < .001 for PrEP regimen comparison in each
group)
• FTC/TAF: -0.6 mL/min vs. FTC/TDF: -4.1 mL/min

• More favorable spine and hip BMD changes through Wk 96 (P < .001)
• FTC/TAF: Spine (+1.0%), Hip (+0.6%) vs. FTC/TDF: Spine (-1.4%), Hip (-1.0%)

Ogbuagu. CROI 2020. Abstr 92.

Slide credit: clinicaloptions.com

DISCOVER: Metabolic Parameters at Wk 96
Median Change From BL at Wk 96

FTC/TAF

FTC/TDF

P Value

Total cholesterol, mg/dL

-3

-14

< .001

LDL cholesterol, mg/dL

-2

-7

< .001

HDL cholesterol, mg/dL

-1

-4

< .001

Triglycerides, mg/dL

+3

-4

< .001

Fasting glucose, mg/dL

+2

+2

.63

Total cholesterol:HDL ratio

+0.1

0

.18

Median body weight, kg

+1.7

+0.5

< .001

§ Wk 96 median BMI: 25.9 with FTC/TAF vs 25.4 with FTC/TDF (P < .001)
̶

BL BMI 25.3 in both arms

Ogbuagu. CROI 2020. Abstr 92.

Slide credit: clinicaloptions.com

Messaging:
- Descovy is an alternative, non-inferior, safe and effective daily oral PrEP
option for men who have sex with men and transgender women who
have sex with men.
- It is not superior nor a “better PrEP.”
- Can be considered in people who are at risk for renal impairment and
osteoporosis, older age.
-4.1
-1.0%
-7
+0.5kg

96 w

-0.6
+0.6 %
-2
+1.7 kg

Talking Points

The importance of
including cisgender
women in research
• Unknown relative importance of serum
vs. tissue drug levels to provide
protection against HIV
• Increased risk of HIV acquisition per sex
act in late pregnancy and postpartum
• There is no established safety database
for TAF/FTC in pregnancy
• Concerns for increased weight gain in
women on TAF.

CDC, 2018; UNAIDS. Fact Sheet—Global AIDS Update 2019 Published July 2019.; Thomsen et al. CROI 2018.

The importance
of prescribing
PrEP to
cisgender
women

• Globally, more than 48% of new HIV infections
are among cis women.
• Cis-gender women make up 1 in 5 new HIV
infections in the United States, yet fewer than 1
in 10 are on PrEP.
• Women-controlled option

Adolescents and PrEP
• 2018, FDA approved TDF/FTC (Truvada) use for adolescents weighing
>35 kg (77 lbs) for pre-exposure prophylaxis
• Unique aspects of providing PrEP among adolescents:

✔ Provider may provide service to minor without parental or guardian
consent

Hosek et al. JAMA Ped. 2017; Hosek et al. J Acquir Immune Defic Syndrome. 2017
https://www.cdc.gov/hiv/policies/law/states/minors.html

Safety

Adherence

Legal

Cost

Paying for PrEP

HHS launched this program in December 2019 as
part of the government’s “End the HIV Epidemic”
initiative

Case 2: On-Demand PrEP
• 36-year-old man presents for STI screening
• MSM
• He only has sex once a month, usually planned
• Is interested in pre-exposure prophylaxis, but does not want to take a
daily medicaAon
• What do you recommend?

What do you recommend?
a)
b)
c)
d)
e)

No PrEP
Daily TDF/FTC
On-demand TDF/FTC
Daily TAF/FTC
On-demand TAF/FTC

On-Demand PrEP (TDF/FTC; Truvada)
• Other terms: “non-daily PrEP,” ”event-driven PrEP,” or “2-1-1 PrEP”
• Off-label use
• Recommended as an alternative to daily PrEP by International Antiviral
Society-USA and European AIDS Clinical Society for men who have sex with
men
• Not yet recommended in the 2017/2018 CDC PrEP Guidelines

Saag et al. JAMA. 2018; https://eacs.sanfordguide.com/art/pre-exposure-prophylaxis; CDC, 2018

How is 2-1-1 done?

2-1-1

Saberi P. and Scott HM. J Gen Intern Med. 2019

How is 2-1-1 done?

Saberi P. and Scott HM. J Gen Intern Med. 2019

How is 2-1-1 done?

Saberi P. and Scott HM. J Gen Intern Med. 2019

IPERGAY Findings
- RCT in France and Canada of MSM
and TGW randomized to ondemand PrEP vs. Placebo
- Median # of pills per month: 15
- 16 new HIV infections
- TDF-FTC: 2 (0.91/100 PY)
- Placebo: 14 (6.60/100 PY
- Relative risk reduction of 86% (95%
CI, 40-98; P=0.002)
- NNT 17
Molina et al. New Engl J Med. 2015

• Open-label extension of the
Findings
IPERGAY trial
§ Low incidence of HIV infections
• All par9cipants were oﬀered on§ On-demand: 0.19/100 PY
demand PrEP (n=361)
§ Placebo: 6.6/100 PY
• Median dura9on of follow-up: 18.4
§ RRR: 97% (CI, 81-100)
months
• Only 2 transgender women (2/361); § Similar safety data as randomized
trial
all other par9cipants were cis men

TDF/FTC PrEP efficacy and Adherence (iPrEx)

Grant RM et al. Lancet Inf.
Disease. 2014

2-3 doses
wk

4 doses and more/week

What about less frequent sex?
• Post-hoc analyses of 270 participants (134 person-years) who had periods of less
frequent sex (15 pills or fewer per month) and high PrEP adherence
IPERGAY RCT

2017 Sub-Analyses

Median # of sex acts/month

10

5

Median # of pills taken/month

15

9.5

Person-years

# HIV
infections

HIV incidence rate/100 py (95% CI)

Placebo

64.8

6

9.3 (3.4-20.1)

TDF/FTC

68.9

0

0.0 (0.0-5.4)

Antoni et al. Lancet HIV. 2020

P

0.013

Who can be offered on-demand PrEP?
2-1-1 PrEP

Daily PrEP

Who can use it?

Only studied in MSM
Small numbers of TGW who have
sex with men (no frontal sex)

Anyone

Chronic HBV

Can trigger a flare

Can be used safely

Planning

Need to plan sex at least 2 hours in
advance

No planning needed

“Forgiveness”

Not forgiving of missed doses

Forgiving of missed doses during
the week

Slide credit: Scott, H. 2019 Ryan White HIV/AIDS Clinical Conference.

What do you recommend?
a) No PrEP (No, the patient should be given the option for taking PrEP
given that he is MSM)
b) Daily TDF/FTC (definitely an option)
c) On-demand TDF/FTC (likely effective if able to adhere to regimen)
d) Daily TAF/FTC (Yes, if willing to take daily, on-demand has not been
studied with TAF/FTC)
e) On-demand TAF/FTC (No, on-demand has not been studied with
TAF/FTC)

Case 3:
• 34 yo MSM presents for routine STI screening.
• He has a remote history of chlamydia and has no other prior STI
history. He is asymptomatic at present and has had 2 new partners
since his last visit 1 year ago. You order labs which return as follows:
• Syphilis EIA Negative
• HIV Ab/AG Non-reactive
• Urine GC PCR: Negative
• Urine CT PCR: Negative

Case Cont'd
• He messages you 1 week later and states that his most recent partner
told him he recently tested positive for chlamydia. The patient denies
any sexual activity since last testing but reports that he has had both
receptive anal and oral intercourse with this partner. He continues to
deny any symptoms at present.
• What (if any) additional testing would you order?

Extragenital Chlamydia and Gonorrhea Among Community Venue–Attending Men
Who Have Sex with Men — Five Cities, United States, 2017

MMWR / April 12, 2019 / 68(14);321–325

• 2371 eligible MSM screened at
community sites in 5 US cities
• 34% had not been screened in
prior yr- rates of STI no different
• Take home: Sexually active MSM
should be screened at least
annually for chlamydia and
gonorrhea at all exposed
anatomic sites; higher risk, every
3-6 months

GU and Extragenital GC/CT among MSM

Association of HIV Preexposure Prophylaxis With Incidence of Sexually
Transmitted Infections Among Individuals at High Risk of HIV Infection
JAMA. 2019;321(14):1380-1390. doi:10.1001/jama.2019.2947

• Overall incidence of STI
91/100person years
• PrEP use was associated with
increased STI Risk, has not been
consistently shown across trials
• In this study extragenital
infections made up 74% of
Chlamydia and 82% Gonococcal
infections

Case Cont'd
• You obtain oropharyngeal and rectal NAAT for Chlamydia and
Gonorrhea. The patient is diagnosed with rectal chlamydia and
prescribed 1g of azithromycin.
• Three months later, he returned to clinic. He denied having receptive
anal intercourse in the interim.
• A repeat rectal swab was collected per patient request, which came
back positive for rectal chlamydia.
• How would you treat him?

Case 3 of persistent rectal chlamydia
A.
B.
C.
D.

Retreat with 1g of azithromycin
Doxycycline 100 mg BID for 7 days
Levofloxacin 500 mg once daily for 7 days
Erythromycin 500 mg four times a day for 7 days

CDC 2015
Treatment
Guidelines

Doxycycline may be more effective at treating
rectal chlamydia than azithromycin
• Meta-analysis (2014) found much higher cure rates with doxycycline
than azithromycin for rectal chlamydia:
• Doxycycline: 99.6%
• Azithromycin: 82.9%
• Efficacy difference: 19.9%, CI: 11.4% to 28.3%

Kong et al. BMC Infect Dis. 2014

Rectal CT are common in women
• 6% of women who attend STI clinic who were tested for rectal
chlamydia tested positive
• 68% of women who tested positive for urogenital chlamydia had
concurrent rectal chlamydia
• 2.2% had rectal only positivity
• Reported anal intercourse was not associated with rectal chlamydia

Chandra et al. Sex Transm Infect. 2018

- Prospective multicenter cohort study
-

Doxycycline 100 mg twice daily for 7 days for women initially positive for rectal CT
Azithromycin 1g single dose in vaginally positive and rectally untested or rectally negative

-

Doxycycline: 95.5%
Azithromycin: 78.5%

-

Doxycycline: 95.4%
Azithromycin: 93.5%

- Microbiological cure for rectal infections:

- Microbiological cure for vaginal infections:

Doxycycline may be
more effective than
azithromycin in
treating rectal CT in
women.

Clinical Considerations
• Azithromycin:
•
•
•
•

1 dose only
Easier to do expedited partner treatment
May take during pregnancy
Effective for genital CT

• Doxycycline:
•
•
•
•

7 day treatment, need to assess for adherence issues
SE: photosensitivity, GI side effects
Contraindicated in pregnancy
May be more effective at treating rectal CT

Case of persistent rectal chlamydia
A.
B.
C.
D.

Retreat with 1g of azithromycin
Doxycycline 100 mg BID for 7 days
Levofloxacin 500 mg once daily for 7 days
Erythromycin 500 mg four times a day for 7 days

Gonococcal Resistance

Gonorrhea Treatment
• Uncomplicated GC infection of urethra, cervix, pharynx, rectum:
• Preferred:
• Ceftriaxone 250mg IM x 1
• Azithromycin 1g PO x 1

• Alternative: (not for pharyngeal infection)
• Cefixime 400mg PO x 1
• Azithromycin 1g PO x 1

• Cephalosporin Allergy:
• Gemifloxacin 320mg PO x 1 OR Gentamycin 240mg IM x 1 + Azithromycin 2g PO x 1

• Disseminated Infection:
• Ceftriaxone 1g IM/IV q day, Azithromycin 1g- Treat for total of 7 days

Case 4: Non-gonococcal urethritis
• 36 yo man who has sex with women presents with a clear penile
discharge and dysuria.
• Empirically treated with azithromycin 1000 mg and ceftriaxone 150
mg IM in clinic.
• Urine GC/CT NAAT collected, along with 4th generation HIV screening
test and treponemal ab. All tests were negative.
• Patient returns a week later with persistent symptoms.
• How would you treat him?

How would you treat him?
A)
B)
C)
D)

Treat with doxycycline 100 mg BID x 7 days
Treat with moxifloxacin 400 mg PO daily x 7 days
Get more testing
Treat with moxifloxacin 400 mg PO daily x 7 days and metronidazole
2 g PO for one dose

Non-gonococcal urethritis is the most common
sexually transmitted syndrome in men
• Major causative organisms of urethritis in men:
•
•
•
•
•
•

C. trachomatis (32.7%)
N. gonorrhoeae (24.2%)
M. genitalium (22.2%)
T. vaginalis (5.2%)
Co-infection with C. trachomatis and M. genitalium (5.9%)
Co-infection with C. trachomatis and N. gonorrhoeae (5.9%)

• Other causative organisms (rare): HSV 1/2, adenovirus, Ureaplasma
urealyticum, anaerobes
Gaydos et al. Sex Transm Infect. 2009

Mycoplasma Genitalium
• One of the smallest known free-living organism; smallest genome of
any species!
• Only pathogenic in the urogenital tract
• Men: discharge, dysuria, urethral stinging/itching, penile tip irritation,
asymptomatic
• Women: cervicitis, pelvic inflammatory disease, infertility

Moi et al. BMC Infectious Diseases. 2015; Workowski et al. MMWR Recomm Rep. 2015
Image credit: https://images.app.goo.gl/7gkShz9d9RVWKXHD8

Diagnostic and Treatment Challenges
• FDA approves Hologic’s Aptima M. Gent assay
(Jan 2019) for vaginal, endocervical, urethral
and urine

• Increasing resistance to antibiotics

• Single dose azithromycin can induce macrolide
resistance in M. Gent.

Cure Rates

• Until 2019, there was no FDA-approved
assay to detect M. Gent and macrolide
resistance.

• Widespread use of azithromycin may explain the
rise in M. Gent resistance

• Low cure rates with doxycycline (20-40%).
Preferred first-line for NGU if M gent unknown
b/c:
• 1) reduces organism load
• 2) does not induce resistance

Moi et al. BMC Infectious Diseases. 2015; Mena et al. Clin Infect Dis. 2009; Schwebke et al. Clin Infect Dis. 2011; Manhart et al. Clin Infect Dis. 2013
Chart Credit: UCSF Grand Rounds, Stephanie Cohen, 2019
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-test-aid-diagnosis-sexually-transmitted-infection-known-mycoplasma

NGU: A new treatment approach?
CDC 2015

SFDPH STD Clinic 2019
•
•
•
•

NGU/other syndromes: Doxy 100 mg BID x 7d
NAAT for GC/CT/Mgen
Mgen(+): Moxi 400 mg Qd x 7 days
If moxi fails: Minocycline 100 mg BID x 14 days

Australian Protocol

Modified: Cohen, S. UCSF Grand Rounds.
2019; Durukan et al. Clin Infect Dis. 2019

• NGU/cervicitis/PID/proctitis/contact to MG:
doxy 100 mg BID x 7 d
• NAAT for GC/CT/Mgen & macrolide resistance
mutation (MSM) assay
• Mgen+/MRM+: Moxi 400 mg qd x 7 days
• Mgen+/MRM-: azithro 1g then 500 mg qd x 3d
Cure rates: Doxy/azithro: 95.4%; Doxi/Moxi: 92%

How would you treat him?
A)
B)
C)
D)

Treat with doxycycline 100 mg BID x 7 days
Treat with moxifloxacin 400 mg PO daily x 7 days
Get more testing, if positive for Mgen à tx with moxifloxacin
Treat with moxifloxacin 400 mg PO daily x 7 days and metronidazole
2 g PO for one dose

Follow-up and Management NGU:
• Treat partners
• If M. gent positive, obtain TOC >3 weeks after treatment
• If GC/CT+, screen for reinfection in 3 months
• If persistent, eval for possible reinfection, resistance or trichomonas
• May treat pre-emptively with metronidazole 2g orally as a single dose or
tinidazole 2g orally in a single dose

Workowski et al. MMWR. 2015

CDC STI Screening Recommendations (2015)
Chlamydia

Gonorrhea

HIV

Syphilis

Trich

HBV

HCV**

Cis-Women

<25 or risk

<25 or risk

13-64yo

*

Hi Prev/risk

Hi Risk

Born 1945-65, Hi
risk

Pregnant

<25 or risk

<25 or risk

All

Yes

HBsAg

Born 194565, Hi risk

MSW

*Hi Prev

*

13-64

*

Hi Risk

Born 194565, Hi risk

MSM

Q3-12mo

Q3-12mo

>q12mo*

Q3-12 mo

Yes

Born 194565, Hi risk

HIV+ M

Dx, q12mo

Dx, q12mo

Dx, 12 mo

HBsAg, cAb, sAb

Dx, q12mo
MSM

HIV+ F

Dx, q12mo

Dx, q12mo

Dx, q12mo Dx, q12mo

HBsAg, cAb, sAb

Dx

Adolescents

F- Yes, M-*hi
Prev

F-Yes, M-*

13+

*

*= consider in high prevalence settings **= USPSTF recommends screening all adults age 18-79

Thank you! Questions?

